FDA grants accelerated approval to brigantinib for ALK NSCLC

the U.S. Food and Drug Administration granted accelerated approval to brigatinib  for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qp055H
via IFTTT